Children with a rare digestive-tract cancer that is resistant to front-line therapy have benefited from a newer targeted therapy that has been shown effective in adults, according to data from a small pilot study that Dana-Farber Cancer Institute researchers were presented at the American Society of Clinical Oncology's annual meeting in Atlanta on Sunday, June 4.
Investigators led by Katherine Janeway, MD, and George Demetri, MD, of the Ludwig Center for Cancer Research at Dana-Farber will discuss results of a preliminary clinical trial in which three children -- two teenagers and a pre-teen -- with metastatic Gastrointenstinal Stromal Tumor (GIST) resistant to imatinib (Gleevecb) were treated with sunitinib (Sutentb).
Sutent was recently approved by the FDA for use in GIST patients as a multi-targeted "smart drug" that inhibits several growth-stimulating kinase enzymes in cancer cells. With sunitinib therapy, the GIST lesions stabilized or decreased in size in all three pediatric patients, with one patient experiencing a complete remission of two cancerous lung nodules. Positron emission tomography (PET) scanning, a sophisticated imaging technique, in two patients showed significant decreases in tumor-related activity at all sites where the disease was present. Side effects of sunitinib were manageable in all three patients.
GIST most often occurs in people over the age of 40 and can arise anywhere in the gastrointestinal tract. Studies have estimated that there are at least 5,000 new cases a year in the United States. Very rare in children, GIST was found to account for less than 5 percent of all cases of the disease at one major cancer center.